Telix Pharmaceuticals Limited (TLPPF)
OTCMKTS · Delayed Price · Currency is USD
7.00
-0.10 (-1.41%)
Feb 5, 2026, 4:00 PM EST
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $390.36M in the half year ending June 30, 2025, with 165.59% growth. This brings the company's revenue in the last twelve months to $664.23M, up 55.35% year-over-year. In the year 2024, Telix Pharmaceuticals had annual revenue of $484.69M with 41.49% growth.
Revenue (ttm)
664.23M
Revenue Growth
+55.35%
P/S Ratio
3.52
Revenue / Employee
1.57M
Employees
431
Market Cap
2.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 484.69M | 142.12M | 41.49% |
| Dec 31, 2023 | 342.57M | 233.76M | 214.82% |
| Dec 31, 2022 | 108.81M | 103.29M | 1,870.12% |
| Dec 31, 2021 | 5.52M | 1.50M | 37.33% |
| Dec 31, 2020 | 4.02M | 1.57M | 64.26% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 292.21M |
| Vaxart | 148.20M |
| Silence Therapeutics | 25.83M |
| Nuo Therapeutics | 2.61M |
| Northwest Biotherapeutics | 937.00K |
| Arch Biopartners | 198.11K |
Telix Pharmaceuticals News
- 16 days ago - Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure - Benzinga
- 16 days ago - Telix Pharmaceuticals Reports Strong Full-Year Revenue, But Shares Remain Under Pressure - Benzinga
- 16 days ago - Independence Bank of Kentucky Buys 66 Shares of Telix Pharmaceuticals Ltd (TLX) - GuruFocus
- 16 days ago - Telix Pharmaceuticals (TLX): Analyst Reiterates 'Buy' Rating with $20 Price Target | TLX Stock News - GuruFocus
- 17 days ago - Telix Pharmaceuticals Q4 Revenue Climbs - Nasdaq
- 24 days ago - Oversold Conditions For Telix Pharmaceuticals (TLX) - Nasdaq
- 25 days ago - Telix Pharmaceuticals Ltd at JPMorgan Healthcare Conference Transcript - GuruFocus
- 25 days ago - Telix Pharmaceuticals Limited (TLX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha